Martingale Asset Management L P Crinetics Pharmaceuticals, Inc. Transaction History
Martingale Asset Management L P
- $4.01 Billion
- Q4 2024
A detailed history of Martingale Asset Management L P transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Martingale Asset Management L P holds 22,484 shares of CRNX stock, worth $770,301. This represents 0.03% of its overall portfolio holdings.
Number of Shares
22,484
Previous 22,074
1.86%
Holding current value
$770,301
Previous $1.13 Million
1.95%
% of portfolio
0.03%
Previous 0.03%
Shares
5 transactions
Others Institutions Holding CRNX
# of Institutions
255Shares Held
89.5MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$311 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$238 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$213 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$210 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$186 Million0.03% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.84B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...